Connect
MJA
MJA

HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths

William Sievert, Homie Razavi, Alexander Thompson, Amany Zekry, Gregory J Dore and Stuart Keith Roberts
Med J Aust 2015; 202 (9): 479. || doi: 10.5694/mja15.00165
Published online: 18 May 2015

To the Editor: We recently used a modelling approach to describe how the burden of infection with hepatitis C virus (HCV) and the associated health care costs in Australia will increase as the infected population ages.1 We showed that increasing the efficacy of antiviral therapy and the number of patients treated could avert the expected increase in deaths from HCV-related liver disease and in the number of patients with end stage HCV-related liver disease. We did not include the specific costs of new direct-acting antiviral (DAA) regimens, as these are yet to be determined in Australia. We know that the cost of the new regimens has elicited discussion internationally about the ability of payers to meet those costs.

  • William Sievert1
  • Homie Razavi2
  • Alexander Thompson3
  • Amany Zekry4
  • Gregory J Dore5
  • Stuart Keith Roberts6

  • 1 Monash Health and Monash University, Melbourne, VIC.
  • 2 Center for Disease Analysis, Louisville, Colorado, USA.
  • 3 St Vincent's Hospital Melbourne, Melbourne, VIC.
  • 4 St George Hospital, Sydney, NSW.
  • 5 Kirby Institute for Infection and Immunity in Society, Sydney, NSW.
  • 6 Alfred Hospital, Melbourne, VIC.


Competing interests:

William Sievert has been a member of advisory boards and a clinical investigator for Bristol Myers Squibb (BMS), Gilead Sciences, Merck, Janssen and AbbVie. Homie Razavi is a director at the Center for Disease Analysis (CDA) and has not received any direct financial remuneration from outside organisations. CDA receives support from public and private firms (Gilead Sciences, AbbVie, and Merck) for non-product related research projects. Alexander Thompson has been a consultant for Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and Roche, and a principal investigator for Gilead, Merck, Roche, BMS, Janssen, Arrowhead and Springbank; he has also received research and grant support from Gilead, Merck, BMS and Abbvie. Amany Zekry has been a member of advisory boards and a clinical investigator for BMS, Gilead Sciences, Merck, and AbbVie. Gregory Dore has been a member of advisory boards and a clinical investigator for BMS, Gilead Sciences, Merck, AbbVie, and Janssen. Stuart Roberts has been a member of advisory boards and a clinical investigator for BMS, Gilead Sciences, Merck, Janssen and AbbVie.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.